Post-earnings recap
Reported
Thu, Feb 13, 2025
EPS actual
$0.06
EPS est.
$-0.68
EPS surprise
+108.78%
1-day move
-0.40%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 0.4%. This may reflect investor concerns about the lack of revenue data and future guidance, despite management's optimistic outlook on their pipeline and clinical trials.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.06 | N/A | +108.78% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed optimism about their future projects while acknowledging the challenges ahead. They did not provide specific guidance for the upcoming quarters.
Management highlighted strong progress in pipeline development.
They emphasized the importance of upcoming clinical trials.
There was a focus on maintaining operational efficiency.